Highlights From the 2019 American Headache Society Annual Scientific Meeting
This week’s edition features highlights from NeurologyLive’s coverage of the American Headache Society’s annual scientific meeting.
This week, Neurology News Network highlights coverage of the 2019 American Headache Society's Annual Scientific Meeting. (transcript below).
Jenna:
Welcome to Neurology News Network. I’m Jenna Payesko. This week’s edition features highlights from NeurologyLive’s coverage of the American Headache Society’s annual scientific meeting, which took place July 11th to 14th in Philadelphia, Pennsylvania. Let’s get into the news.
Orally administered atogepant, a small molecule CGRP receptor antagonist, demonstrated a statistically significant and clinically relevant reduction in mean migraine days compared with placebo while eliciting no treatment-related serious adverse events, according to findings from a phase 2b/3 study.
At the lowest dose administered, there was a 4-day reduction in mean monthly migraine days compared with a reduction of 2.85 days in the placebo group. This benefit remained consistent across the 5 doses of atogepant explored in the study. Among those who received the highest dose, there was a 4.14-day mean reduction in monthly migraine days.
Treatment with eptinezumab is associated with substantial improvements in HIT-6 score and migraine-related burden, according to results from the ongoing, open-label PREVAIL study. The study is evaluating the long-term safety of repeat doses of 300 mg eptinezumab every 3 months in patients with chronic migraine.
Eptinezumab, which is delivered via quarterly infusion, is currently under review by the FDA for the preventive treatment of episodic and chronic migraine. In total, data were collected from 128 patients in the primary treatment phase. Mean HIT-6 total scores decreased from 65.2 at baseline to 57.1 at month 1, with reductions generally similar through months 3 through 12, all of which were significant.
To gain further insight on the meeting’s hot topics, NeurologyLive sat down with Dr. Stephen Silberstein, past AHS president and director of the Jefferson Headache Center. In the interview, Dr. Silberstein recounted key presentations as well as topics that generated lively debates at the meeting. Let’s take a look.
For more direct access to expert insight and conference updates, head to neurologylive.com. This has been Neurology News Network. Thanks for watching.
